Willem M. L. L. G. Deserno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Willem M. L. L. G. Deserno has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Jelle O. Barentsz
2 shared publicationsAnsje S. Fortuin
1 shared publicationChristina A. Hulsbergen van de Kaa
1 shared publicationD. Kaufmann
1 shared publicationEmile N.J.T. van Lin
1 shared publicationGerrit J. Jager
1 shared publication
Latest Publications
- 1 September 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81 (1) , 8-15
Comparison of Nodal Risk Formula and MR Lymphography for Predicting Lymph Node Involvement in Prostate Cancer
- 1 September 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 81 (1) , 8-15
Comparison of Nodal Risk Formula and MR Lymphography for Predicting Lymph Node Involvement in Prostate Cancer
- 1 November 2004
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 233 (2) , 449-456
Urinary Bladder Cancer: Preoperative Nodal Staging with Ferumoxtran-10–enhanced MR Imaging
PURPOSE: To prospectively evaluate ferumoxtran-10–enhanced magnetic resonance (MR) imaging for nodal staging in patients with urinary bladder cancer. MATERIALS AND METHODS: Fifty-eight patients with proved bladder cancer were enrolled. Results of MR imaging performed before and after injection of ferumoxtran-10 were compared with histopathologic results in surgically removed lymph nodes. High-spatial-resolution three-dimensional T1-weighted magnetization-prepared rapid acquisition gradient-echo (voxel size, 1.4 × 1.4 × 1.4 mm) and T2*-weighted gradient-echo (voxel size, 0.8 × 0.8 × 3.0 mm) sequences were performed before and 24 hours after injection of ferumoxtran-10 (2.6 mg iron per kilogram of body weight). On precontrast images, lymph nodes were defined as malignant by using size and shape criteria (round node, >8 mm; oval, >10 mm axial diameter). On postcontrast images, nodes were considered benign if there was homogeneous decrease in signal intensity and malignant if decrease was absent or heterogene...
- 1 November 2004
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 233 (2) , 449-456
Urinary Bladder Cancer: Preoperative Nodal Staging with Ferumoxtran-10–enhanced MR Imaging
PURPOSE: To prospectively evaluate ferumoxtran-10–enhanced magnetic resonance (MR) imaging for nodal staging in patients with urinary bladder cancer. MATERIALS AND METHODS: Fifty-eight patients with proved bladder cancer were enrolled. Results of MR imaging performed before and after injection of ferumoxtran-10 were compared with histopathologic results in surgically removed lymph nodes. High-spatial-resolution three-dimensional T1-weighted magnetization-prepared rapid acquisition gradient-echo (voxel size, 1.4 × 1.4 × 1.4 mm) and T2*-weighted gradient-echo (voxel size, 0.8 × 0.8 × 3.0 mm) sequences were performed before and 24 hours after injection of ferumoxtran-10 (2.6 mg iron per kilogram of body weight). On precontrast images, lymph nodes were defined as malignant by using size and shape criteria (round node, >8 mm; oval, >10 mm axial diameter). On postcontrast images, nodes were considered benign if there was homogeneous decrease in signal intensity and malignant if decrease was absent or heterogene...